A Phase 2a Dosefinding Study of Namodenoson, an A3AR Agonist, in Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Time: 1:30 pm
day: Day 2 Stream 3 PM

Details:

• General background of our target
• Revealing our protocol and study results
• How we designed our Phase 2a trial

Speakers: